PAMS: New Capacity Is Coming, but Will Demand Be Clean Enough to Fill It

What This Follow-Up Is Isolating

The main article on PAMS argued that 2026 will not be judged by survival, leverage, or even by reported profitability alone, but by whether the company can turn profit, capacity, and cash into a cleaner growth base. This follow-up takes one thread from that broader thesis: the 2024-2025 equipment cycle, the fact that much of its impact is pushed into Q2 2026, and the gap between adding theoretical capacity and adding demand that is actually worth building around.

That matters because the headline 25% number can be read too quickly. A superficial read says PAMS is about to remove a manufacturing bottleneck, so once the new equipment is installed the next stage should simply open up. But the same filing says something else as well: as of the report date, the company does not face a production-capacity constraint, it still has production redundancy, and it is operating at about 90% of potential output. That means the new equipment is not solving a bottleneck that is already choking the business. It is an option on future demand.

That distinction is the whole point. When capacity is the true bottleneck, CAPEX solves the problem. When demand quality is the bottleneck, CAPEX mainly raises the proof burden. In PAMS's case, the filing leaves little doubt which bucket this belongs to.

What Was Actually Bought, and What Is Already Running

The filing describes four separate equipment moves, not one single project. That matters because it separates equipment that is already active from equipment whose economic effect is still deferred into 2026.

That table sharpens the key point. Not all of 2025 CAPEX has turned into active capability yet. Some of the most important Israeli equipment is still sitting between purchase and installation, so 2025 is mainly a year of capital commitment, not a year of full economic conversion.

Note 11 adds an important second layer. Property, plant and equipment additions jumped to $9.44 million in 2025 from $4.69 million in 2024, and $9.07 million of that 2025 spend was machinery and equipment. At the same time, the book value of machinery and equipment rose to $19.06 million from $13.03 million. At the capital-allocation level, PAMS clearly moved from routine upkeep into a real expansion cycle.

But there is a nuance here too. The company repeatedly says that each individual equipment step is not material on its own. That does not cancel the fact that the cumulative cycle is larger. It does mean management is building the new capacity in layers, not through one single transformative jump that would by itself change the economics of the business.

The New Capacity Does Not Solve an Existing Bottleneck

This is the heart of the continuation thesis. The production-capacity section is almost paradoxical at first glance. The company says production in Israel and the U.S. is carried out continuously, around the clock, at full operation. In the same breath, it says it can still increase output through more intensive use of its machines, additional labor from external sources, and subcontractors. It then sharpens the point further: as of the report date, it has no production-capacity limitation and is working at roughly 90% of potential output.

That is the critical detail. Continuous operation is not the same thing as fully exhausting the installed base. PAMS is describing plants that run around the clock but still retain operating headroom. So even before the equipment planned for Q2 2026 arrives, the company is not presenting 2025 as a year in which it lost orders because it had nowhere to produce them.

The implication is more important than the headline. The roughly 25% increase in Israeli capacity is not being introduced to release a bottleneck already visible in the current filing. It is being introduced to prepare the ground if demand justifies it, while also improving product quality and keeping the company at the technological frontier. This is offensive CAPEX, not rescue CAPEX.

That is also why the equipment alone is hard to treat as a standalone trigger. If there is already redundancy before installation, the return on the investment will not come from the mere existence of a new machine. It will come only if the company can fill that machine with orders that improve the economic quality of the business, not just its theoretical production envelope.

If So, the Real Problem Is Order Quality

To understand why capacity is not the whole story, it has to be linked back to the customer section. PAMS has a diversified customer list, but most of that business is handled through ad hoc orders with no commitment to future purchasing. A framework agreement exists only with customer A. In the same year, customer A accounted for 42% of sales and customer D for another 18%.

This is exactly where "demand" and "demand quality" stop being the same thing.

Gross demand simply means more orders can show up. Demand quality means something stricter: the orders are more repeatable, less concentrated, less dependent on two names, and less exposed to one-off events or opportunistic tender flow. The filing does not yet prove that kind of demand quality. If anything, it says the opposite. It explicitly notes that much of the military and governmental environment depends on tenders and defense budgets, and that continued purchases by long-standing customers are not assured.

That is why the right way to read the 25% figure is not as an answer in itself. The new capacity is only the shell. What has to fill it is a cleaner demand layer: real penetration into new markets, a broader product set, better customer diversification, or better forward visibility on orders. All of those themes appear in the forward-looking section, but they still appear as plans, evaluations, marketing efforts, and partnership options, not as contracted backlog.

The good news for PAMS is that management is presenting this as deliberate preparation, not as a response to a bottleneck that has already frozen the business. The less comfortable part is that the market can afford to stay demanding. As long as most customers remain ad hoc and only customer A enjoys a framework agreement, equipment spend by itself will not make the story cleaner.

What Needs To Be Seen Over The Next Few Quarters

The first test is technical. The equipment purchased in Q1 and Q3 2025 has to arrive and be installed in Q2 2026 without another delay. Without that, even the capacity option remains theoretical.

The second test matters more. After installation, the company has to show that the added capacity is translating into something more valuable than extra operating flexibility. The strongest signals would be a less concentrated customer mix, orders that look less opportunistic, and evidence that the product and technology upgrades are actually opening new markets or applications.

The third test is the quality of the return on that investment. If 2026 brings more equipment and more capacity but not better order visibility, PAMS will still look like an operationally strong company with an open commercial question. If, on the other hand, the new capacity comes together with a broader demand base, then the 2024-2025 equipment cycle will look like correct preparation rather than CAPEX that arrived before the proof.

Bottom Line

PAMS invested more in equipment across 2024 and 2025, and that is a clear sign that management wants to prepare the business for its next phase. But the filing itself makes clear that the next phase is still not about capacity alone. The company retains headroom, does not identify an active production constraint, and part of the new equipment is still only expected to enter operation in Q2 2026.

So the stricter reading is that the new equipment does not solve the bottleneck. It relocates it. The bottleneck moves from the plant floor to the order book, from "can the company produce more" to "who is ready to buy more, in what volume, and with what visibility."

If that shift materializes, the new capacity will be seen as the right base for growth. If it does not, the company will simply be left with a wider production cushion and still not enough proof that production capacity was the real problem in the first place.